查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球原位雜交(ISH)市場：按產品（消耗品,儀器,軟件）,技術（DNA FISH,RNA FISH,PNA FISH,CISH）,應用（癌症,免疫學,神經科學,細胞,診斷）,用戶預測到2027
市場調查報告書
商品編碼
1151637

全球原位雜交(ISH)市場：按產品（消耗品,儀器,軟件）,技術（DNA FISH,RNA FISH,PNA FISH,CISH）,應用（癌症,免疫學,神經科學,細胞,診斷）,用戶預測到2027

In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User(Hospitals, Pharma, Biotech, CROs) -Global Forecast -2027
出版日期: | 出版商: MarketsandMarkets | 英文 193 Pages | 訂單完成後即時交付

價格
簡介目錄

全球ISH（原位雜交）市場規模將從 2022 年的 15 億美元增長到 2027 年的 28 億美元，預測期內復合年增長率為 12.6%。

伴隨診斷產品顯示出改善癌症診斷和治療的巨大潛力。基於 FISH 的生物標誌物在伴隨診斷學的發展中發揮著重要作用，因為它們可以同時評估形態學和基因擴增。這推動了在伴隨診斷測試中採用基於 ISH 的耗材。

“試劑盒和試劑部分將在 2021 年 ISH 耗材市場收入中佔據最高份額”

ISH 市場分為三種主要產品：耗材、設備和軟件。 ISH 耗材市場進一步細分為試劑盒/試劑、探針和配件。該試劑盒的優點是易於使用、即用型試劑和抗體、優化的抗體對抗原的敏感性以及低錯誤可能性。這促使在診斷工具中使用試劑盒來確認特定藥物在癌症患者治療過程中的應用。

“2021 年醫院和臨床實驗室將佔 ISH 市場最大的收入份額”

全球 ISH 市場按最終用戶細分為醫院/臨床實驗室、學術/研究機構、CRO 和製藥/生物技術公司。醫院和臨床實驗室部門將在 2021 年獲得最高收入。不斷增長的患者人數、增加在醫院進行的實驗室測試的醫療保險報銷以及先進診斷測試的出現是推動這一最終用戶細分市場增長的主要因素。

“亞太地區：ISH 市場增長最快的國家/地區”

ISH 市場分為北美、歐洲、亞太地區和世界其他地區。預計亞太地區 ISH 市場將在預測期內以最高複合年增長率增長。經濟增長、人口基數大、慢性病患病率上升、生活水平提高、對優質醫療保健的需求增加、醫療保健支出增加、政府舉措以及該地區國家組織診斷測試的可用性使用意識和其他因素是關鍵推動亞太地區市場增長的因素。

內容

第一章介紹

第二章研究方法論

第 3 章執行摘要

第 4 章重要注意事項

第 5 章市場概述

  • 介紹
  • 市場動態
    • 司機
    • 機會
    • 任務
  • 波特的五力分析
  • 供應鏈分析
  • 價值鏈分析
  • 生態系統分析
  • 主要會議和活動
  • 監管分析 (ISH)
  • 價格分析

第 6 章 ISH（原位雜交）市場：副產品

  • 介紹
  • 消耗品
    • 調查
    • 試劑盒和試劑
    • 配飾
  • 設備
  • 軟件

第 7 章 ISH（原位雜交）市場：按技術分類

  • 介紹
  • 魚
    • DNA
    • 核糖核酸
    • 巴拿馬民族聯盟
  • CISH

第 8 章 ISH（原位雜交）市場：按應用

  • 介紹
  • 癌症診斷
  • 細胞學
  • 傳染病診斷
  • 神經科學
  • 免疫學

第 9 章 ISH（原位雜交）市場：按最終用戶分類

  • 介紹
  • 醫院和臨床實驗室
  • 學術和研究機構
  • 製藥和生物技術公司
  • 首席風險官

第 10 章 ISH（原位雜交）市場：按地區

  • 介紹
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 其他
  • 其他地區

第11章競爭格局

  • 介紹
  • 主要公司採用的戰略/領先公司的分析
  • 市場份額分析
  • 收益分成分析
  • 企業評估象限
  • 企業評估象限：初創公司/中小企業
  • 競爭情景和趨勢

第12章公司簡介

  • 主要公司
    • ABBOTT
    • F. HOFFMANN-LA ROCHE AG
    • THERMO FISHER SCIENTIFIC INC.
    • DANAHER
    • AGILENT TECHNOLOGIES, INC.
    • BIOCARE MEDICAL, LLC
    • BIO-TECHNE CORPORATION
    • QIAGEN N.V.
    • MERCK KGAA
    • PERKINELMER
    • ENZO BIOCHEM
    • BIO-RAD LABORATORIES
    • ABNOVA CORPORATION
    • BIOGENEX LABORATORIES
    • OPGEN
    • BIO SB
    • ABCAM
    • ZYTOMED SYSTEMS GMBH
    • NEOGENOMICS LABORATORIES
    • BIOVIEW
  • 其他企業
    • GENEMED BIOTECHNOLOGIES
    • CREATIVE BIOARRAY
    • BIOCAT GMBH
    • OXFORD GENE TECHNOLOGY
    • ZYTOVISION

第13章 附錄

簡介目錄
Product Code: BT 3649

The global in situ hybridization market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period. Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.

"The kits & reagents segment accounted for the highest share in the ISH consumables market revenue for the year 2021"

The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.

"Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021"

Based on the end users the global in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.

"Asia Pacific: The fastest-growing country in the in situ hybridization market"

The in situ hybridization market is segmented into North America, Europe, Asia Pacific, RoW. The in situ hybridization market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the countries of this region, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80% and Demand Side 20%
  • By Designation: C-level - 25%, D-level - 20%, and Others - 55%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:

  • Abbott (US)
  • Abcam (UK)
  • Abnova Corporation (Taiwan)
  • Agilent Technologies, Inc. (US)
  • Bio SB Inc. (US)
  • Biocare Medical, LLC (US)
  • BioCat GmbH (Germany)
  • BioGenex Laboratories (US)
  • Bio-Rad Laboratories (US)
  • Bio-Techne Corporation (US)
  • BioView (Israel)
  • Creative Bioarray (US)
  • Danaher (US)
  • Enzo Biochem (US)
  • F. Hoffmann-La Roche AG (Switzerland)
  • GeneMed Biotechnologies Inc. (US)
  • Merck KGaA (Germany)
  • NeoGenomics Laboratories (US)
  • OpGen (US)
  • Oxford Gene Technology (UK)
  • PerkinElmer Inc. (US)
  • QIAGEN N.V. (Netherlands)
  • Thermo Fisher Scientific (US)
  • ZytoVision GmbH (Germany)

Research Coverage:

This report provides a detailed picture of the in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS
  • 1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
    • FIGURE 4 IN SITU HYBRIDIZATION MARKET SIZE (USD MILLION)
    • FIGURE 5 IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022-2027)
    • FIGURE 6 IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
  • 2.3 MARKET DATA ESTIMATION & TRIANGULATION
    • 2.3.1 DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 INDUSTRY INSIGHTS
  • 2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 8 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 FLUORESCENT IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021
    • FIGURE 11 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 IN SITU HYBRIDIZATION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF IN SITU HYBRIDIZATION MARKET

4 PREMIUM INSIGHTS

  • 4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW
    • FIGURE 14 GROWING FOCUS ON COMPANION DIAGNOSTICS AND RISING INCIDENCE OF CANCER & GENETIC DISORDERS TO DRIVE MARKET
  • 4.2 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET
    • FIGURE 15 CONSUMABLES TO COMMAND LARGEST SHARE IN 2021
  • 4.3 IN SITU HYBRIDIZATION MARKET: BY REGION AND END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 16 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT TO GROW AT HIGHEST CAGR IN NORTH AMERICA

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 17 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 1 IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of genetic disorders and cancer
      • 5.2.1.2 Growing awareness of companion diagnostics
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Emerging economies
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Shortage of skilled professionals
  • 5.3 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 2 IN SITU HYBRIDIZATION MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.3.1 THREAT OF NEW ENTRANTS
    • 5.3.2 THREAT OF SUBSTITUTES
    • 5.3.3 BARGAINING POWER OF BUYERS
    • 5.3.4 BARGAINING POWER OF SUPPLIERS
    • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 18 IN SITU HYBRIDIZATION MARKET: SUPPLY CHAIN
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS OF THE IN SITU HYBRIDIZATION MARKET
  • 5.6 ECOSYSTEM ANALYSIS
    • FIGURE 20 IN SITU HYBRIDIZATION MARKET: ECOSYSTEM ANALYSIS
  • 5.7 KEY CONFERENCES & EVENTS (2020-2022)
    • 5.7.1 IN SITU HYBRIDIZATION CONFERENCES (2022)
    • TABLE 3 IN SITU HYBRIDIZATION CONFERENCES (2022)
    • 5.7.2 IN SITU HYBRIDIZATION CONFERENCES (2021)
    • 5.7.3 IN SITU HYBRIDIZATION CONFERENCES (2020)
    • TABLE 4 IN SITU HYBRIDIZATION CONFERENCES (2020)
  • 5.8 REGULATORY ANALYSIS (IN SITU HYBRIDIZATION)
    • 5.8.1 FDA APPROVALS
    • 5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.9 PRICING ANALYSIS
    • TABLE 9 PRICING ANALYSIS OF IN SITU PRODUCTS
    • 5.9.1 IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TREND FOR TREATMENT

6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 10 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
  • 6.2 CONSUMABLES
    • TABLE 11 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 12 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 13 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 14 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 15 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.1 PROBES
      • 6.2.1.1 Preference for direct localization of DNA/RNA sequences using probes
    • TABLE 16 IN SITU HYBRIDIZATION MARKET FOR PROBES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 17 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 18 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.2 KITS & REAGENTS
      • 6.2.2.1 Growing focus on companion diagnostics to drive demand
    • TABLE 20 IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 22 EUROPE: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.3 ACCESSORIES
    • TABLE 24 IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 25 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 RISING DEMAND FOR AUTOMATED SYSTEMS TO SUPPORT MARKET GROWTH
    • TABLE 28 IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 29 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 30 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.4 SOFTWARE
    • 6.4.1 RISING NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET
    • TABLE 32 IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 33 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 34 EUROPE: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)

7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 36 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 7.2 FLUORESCENT IN SITU HYBRIDIZATION
    • TABLE 37 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 38 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 39 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 40 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 41 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.1 DNA FLUORESCENT IN SITU HYBRIDIZATION
      • 7.2.1.1 Rising need to ensure stability of genetic material to drive market
    • TABLE 42 DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 43 NORTH AMERICA: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 44 EUROPE: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 45 ASIA PACIFIC: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.2 RNA FLUORESCENT IN SITU HYBRIDIZATION
      • 7.2.2.1 Increasing biomedical research activity to support market growth
    • TABLE 46 RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 47 NORTH AMERICA: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 48 EUROPE: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 7.2.3 PNA FLUORESCENT IN SITU HYBRIDIZATION
      • 7.2.3.1 Utilization of PNA FISH for infectious disease control to drive market
    • TABLE 50 PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 51 NORTH AMERICA: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 52 EUROPE: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 CHROMOGENIC IN SITU HYBRIDIZATION
    • 7.3.1 COST-EFFECTIVE ALTERNATIVE TO FISH TO SUPPORT MARKET GROWTH
    • TABLE 54 CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 55 NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 56 EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 58 IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 8.2 CANCER DIAGNOSTICS
    • 8.2.1 INCREASING UTILIZATION OF FISH IN COMPANION DIAGNOSTICS TO DRIVE MARKET
    • TABLE 59 IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 60 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 61 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 62 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 CYTOLOGY
    • 8.3.1 IDENTIFICATION OF CYTOGENETIC ALTERATIONS TO DRIVE DEMAND FOR FISH
    • TABLE 63 IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 64 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 65 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 66 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 INFECTIOUS DISEASE DIAGNOSTICS
    • 8.4.1 RISING NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET
    • TABLE 67 IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 68 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 69 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 70 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.5 NEUROSCIENCE
    • 8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR ISH
    • TABLE 71 IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 72 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 73 EUROPE: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 74 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.6 IMMUNOLOGY
    • 8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET
    • TABLE 75 IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 76 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 77 EUROPE: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 78 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)

9 IN SITU HYBRIDIZATION MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 79 IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
    • 9.2.1 HOSPITAL-BASED LABS ARE ACCESSIBLE AND OFFER RAPID TEST RESULTS
    • TABLE 80 IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 81 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 82 EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.3 ACADEMIC & RESEARCH INSTITUTES
    • 9.3.1 INCREASING R&D ACTIVITIES FOR CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET GROWTH
    • TABLE 84 IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 85 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 86 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.4.1 RISING DEMAND FOR PRECISION TREATMENTS TO DRIVE MARKET
    • TABLE 88 IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 89 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 90 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 9.5 CONTRACT RESEARCH ORGANIZATIONS
    • 9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH
    • TABLE 92 IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 93 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 94 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 95 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

10 IN SITU HYBRIDIZATION MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 96 IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT
    • TABLE 97 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 98 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 99 NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 100 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 101 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 102 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027(USD MILLION)
    • TABLE 103 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Rising government funding for life science research to drive market
    • TABLE 104 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 105 US: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 106 US: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 107 US: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 108 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 109 US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing investments in genomics research to drive market
    • TABLE 110 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 111 CANADA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 112 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 113 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 114 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 115 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 116 EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 117 EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 118 EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 119 EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 120 EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 121 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 122 EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Rising demand for technologically advanced diagnostic procedures to drive market
    • TABLE 123 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 124 GERMANY: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 125 GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 126 GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 127 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 128 GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.3.2 FRANCE
      • 10.3.2.1 Growing investments in proteomics and genomics to drive market
    • TABLE 129 FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 130 FRANCE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 131 FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 132 FRANCE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 133 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 134 FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Growing focus on cancer research to drive market for ISH
    • TABLE 135 UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 136 UK: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 137 UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 138 UK: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 139 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 140 UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.3.4 REST OF EUROPE (ROE)
    • TABLE 141 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 142 REST OF EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 143 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 144 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 145 REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 146 REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 22 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT
    • TABLE 147 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 149 ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 150 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 151 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 152 ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 153 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Rising focus on personalized diagnostics products to support market growth
    • TABLE 154 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 155 JAPAN: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 156 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 157 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 158 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 159 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Rising annual R&D investments to drive market demand for FISH and CISH-based kits
    • TABLE 160 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 161 CHINA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 162 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 163 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 164 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 165 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Collaborations between hospitals and diagnostics centers for laboratory services to drive market
    • TABLE 166 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 167 INDIA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 168 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 169 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 170 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 171 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 172 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 173 REST OF ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 174 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 175 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 176 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 177 REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 10.5 REST OF THE WORLD (ROW)
    • TABLE 178 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 179 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 180 REST OF THE WORLD: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 181 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)
    • TABLE 182 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 183 REST OF THE WORLD: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 184 REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT-TO-WIN ANALYSIS
    • FIGURE 23 IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 24 IN SITU HYBRIDIZATION MARKET: MARKET SHARE ANALYSIS FOR KEY PLAYERS (2021)
  • 11.4 REVENUE SHARE ANALYSIS
    • FIGURE 25 REVENUE ANALYSIS FOR KEY COMPANIES (2019-2021)
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 26 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021)
  • 11.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 27 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION QUADRANT (2021)
    • 11.6.5 COMPETITIVE BENCHMARKING
      • 11.6.5.1 In situ hybridization market: Startups/SMEs
    • TABLE 185 LIST OIN SITU HYBRIDIZATION MARKET: STARTUPS/SMES
      • 11.6.5.2 In situ hybridization market: Competitive benchmarking of key players [startups/SMEs)
    • TABLE 186 IN SITU HYBRIDIZATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]
  • 11.7 COMPETITIVE SCENARIO AND TRENDS
    • 11.7.1 DEALS
    • TABLE 187 IN SITU HYBRIDIZATION MARKET: DEALS
    • 11.7.2 PRODUCT LAUNCHES
    • TABLE 188 IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES

12 COMPANY PROFILES

  • 12.1 KEY COMPANIES
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 12.1.1 ABBOTT
    • TABLE 189 ABBOTT: BUSINESS OVERVIEW
    • FIGURE 28 ABBOTT: COMPANY SNAPSHOT
    • TABLE 190 ABBOTT: PRODUCTS OFFERED
    • 12.1.2 F. HOFFMANN-LA ROCHE AG
    • TABLE 191 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
    • FIGURE 29 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
    • TABLE 192 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
    • TABLE 193 F. HOFFMANN-LA ROCHE LTD: PRODUCT APPROVALS
    • 12.1.3 THERMO FISHER SCIENTIFIC INC.
    • TABLE 194 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • TABLE 195 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED
    • 12.1.4 DANAHER
    • TABLE 196 DANAHER: BUSINESS OVERVIEW
    • FIGURE 31 DANAHER: COMPANY SNAPSHOT
    • TABLE 197 DANAHER: PRODUCTS OFFERED
    • TABLE 198 PRODUCT APPROVALS
    • 12.1.5 AGILENT TECHNOLOGIES, INC.
    • TABLE 199 AGILENT TECHNOLOGIES, INC: BUSINESS OVERVIEW
    • TABLE 200 AGILENT TECHNOLOGIES, INC: PRODUCTS OFFERED
    • 12.1.6 BIOCARE MEDICAL, LLC
    • TABLE 201 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW
    • TABLE 202 BIOCARE MEDICAL, LLC: PRODUCTS OFFERED
    • 12.1.7 BIO-TECHNE CORPORATION
    • TABLE 203 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
    • TABLE 204 BIO-TECHNE: PRODUCT LAUNCHES
    • 12.1.8 QIAGEN N.V.
    • TABLE 205 QIAGEN N.V.: BUSINESS OVERVIEW
    • TABLE 206 QIAGEN N.V.: PRODUCTS OFFERED
    • 12.1.9 MERCK KGAA
    • TABLE 207 MERCK KGAA: BUSINESS OVERVIEW
    • TABLE 208 MERCK KGAA: PRODUCTS OFFERED
    • 12.1.10 PERKINELMER
    • TABLE 209 PERKINELMER: BUSINESS OVERVIEW
    • TABLE 210 PERKINELMER: PRODUCTS OFFERED
    • 12.1.11 ENZO BIOCHEM
    • TABLE 211 ENZO BIOCHEM: BUSINESS OVERVIEW
    • FIGURE 37 ENZO BIOCHEM: COMPANY SNAPSHOT
    • TABLE 212 ENZO BIOCHEM: PRODUCTS OFFERED
    • 12.1.12 BIO-RAD LABORATORIES
    • TABLE 213 BIO-RAD LABORATORIES: BUSINESS OVERVIEW
    • TABLE 214 BIO-RAD LABORATORIES: PRODUCTS OFFERED
    • 12.1.13 ABNOVA CORPORATION
    • TABLE 215 ABNOVA CORPORATION: BUSINESS OVERVIEW
    • TABLE 216 ABNOVA CORPORATION: PRODUCTS OFFERED
    • 12.1.14 BIOGENEX LABORATORIES
    • TABLE 217 BIOGENEX LABORATORIES: BUSINESS OVERVIEW
    • TABLE 218 BIOGENEX LABORATORIES: PRODUCTS OFFERED
    • 12.1.15 OPGEN
    • TABLE 219 OPGEN: BUSINESS OVERVIEW
    • TABLE 220 OPGEN INC: PRODUCTS OFFERED
    • 12.1.16 BIO SB
    • TABLE 221 BIO SB: BUSINESS OVERVIEW
    • TABLE 222 BIO SB: PRODUCTS OFFERED
    • 12.1.17 ABCAM
    • TABLE 223 ABCAM: BUSINESS OVERVIEW
    • TABLE 224 ABCAM: PRODUCTS OFFERED
    • 12.1.18 ZYTOMED SYSTEMS GMBH
    • TABLE 225 ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW
    • TABLE 226 ZYTOMED SYSTEMS: PRODUCTS OFFERED
    • 12.1.19 NEOGENOMICS LABORATORIES
    • TABLE 227 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW
    • TABLE 228 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED
    • 12.1.20 BIOVIEW
    • TABLE 229 BIOVIEW: BUSINESS OVERVIEW
    • TABLE 230 BIOVIEW: PRODUCTS OFFERED
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 GENEMED BIOTECHNOLOGIES
    • TABLE 231 GENEMED BIOTECHNOLOGIES: BUSINESS OVERVIEW
    • 12.2.2 CREATIVE BIOARRAY
    • TABLE 232 CREATIVE BIOARRAY: BUSINESS OVERVIEW
    • 12.2.3 BIOCAT GMBH
    • TABLE 233 BIOCAT GMBH: BUSINESS OVERVIEW
    • 12.2.4 OXFORD GENE TECHNOLOGY
    • TABLE 234 OXFORD GENE TECHNOLOGY: BUSINESS OVERVIEW
    • 12.2.5 ZYTOVISION
    • TABLE 235 ZYTOVISION: BUSINESS OVERVIEW

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS